R. Michael Gendreau
2020
In 2020, R. Michael Gendreau earned a total compensation of $30K as Chief Medical Officer at Virios Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $30,000 |
|---|---|
| Total | $30,000 |
Gendreau received $30K in non-equity incentive plan, accounting for 100% of the total pay in 2020.
Rankings
In 2020, R. Michael Gendreau's compensation ranked 13,008th out of 13,090 executives tracked by ExecPay.
| Classification | Ranking | Percentile |
|---|---|---|
All | 13,008 out of 13,090 | 1st |
Division Manufacturing | 5,586 out of 5,618 | 1st |
Major group Chemicals And Allied Products | 2,239 out of 2,251 | 1st |
Industry group Drugs | 1,941 out of 1,951 | 1st |
Industry Pharmaceutical Preparations | 1,449 out of 1,456 | 1st |
Source: SEC filing on April 26, 2022.
Gendreau's colleagues
We found five more compensation records of executives who worked with R. Michael Gendreau at Virios Therapeutics in 2020.
2020
Greg Duncan
Virios Therapeutics
Chief Executive Officer
2020
Richard Burch
Virios Therapeutics
President
2020
William Pridgen
Virios Therapeutics
Chief Executive Officer
2020
Angela Walsh
Virios Therapeutics
Vice President of Finance
2020
Ralph Grosswald
Virios Therapeutics
Vice President of Operations
News
Virios Therapeutics CEO Greg Duncan's 2023 pay falls 39% to $567K
April 25, 2024
Virios Therapeutics CEO Greg Duncan's 2022 pay slips 15% to $937K
April 27, 2023
Virios Therapeutics CEO Greg Duncan's 2021 pay falls 69% to $1.1M
April 26, 2022
Virios Therapeutics CEO Greg Duncan receives $3.5M in 2020
April 28, 2021